PCV15

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

ImmunodeficiencyPneumococcal Disease

296 competitors in Immunodeficiency

#DrugCompanyPhaseTrials

1

Viread

Gilead

Phase 3

12

Farxiga

AstraZeneca

Phase 3

13

Repatha

Amgen

Phase 3

14

Emtriva

Gilead

Phase 3

15

Edurant Ped

WWim Janssens

Phase 3

86

Vemlidy

Gilead

Phase 3

—7

Immunoglobulin

Sanofi

Phase 3

28

Atripla

Gilead

Phase 3

39

PPSV23

Merck & Co.

Phase 3

110

Darunavir/ritonavir

GSK

Phase 3

1Show 33 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunogenicity2 trials

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

Completed·Merck & Co.·Phase 3·NCT05420961·717 enrolled

Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

Completed·Pfizer·Phase 1·NCT05489328·394 enrolled

Pneumococcal Disease2 trials

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

Completed·Merck & Co.·Phase 3·NCT05696080·518 enrolled

A Phase 2, Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants

Active, not recruiting·Pfizer·Phase 2·NCT06524414·605 enrolled

Pneumococcal Vaccines1 trial

Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15

Recruiting·UUniversity of Oxford·Phase 4·NCT06731374·106 enrolled

Immunodeficiency1 trial

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

Completed·Merck & Co.·Phase 3·NCT05393037·313 enrolled

Vaccination1 trial

MISP 60528 Pneumococcal Vaccination

Terminated·MMontefiore Medical Center··NCT04845945·4 enrolled

Details

Drug Info

Related News